| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
as an immunotherapeutic protein
Bioanalytical Development, Schering-Plough Research Institute, Union, New Jersey
Correspondence: Michael J. Grace, Bioanalytical Development, Schering-Plough Research Institute, U-13-2-2050, 1011 Morris Ave., Union, NJ 07083. E-mail: michael.grace{at}spcorp.com
Interferon-
(IFN-) has proven to be a clinically effective antiviral and antineoplastic therapeutic drug for more than 16 years. During this time, evidence from in vitro laboratory studies and the clinical arena has supported the concept that IFN- is an immunotherapeutic drug. By regulating a diverse set of cytokines and their receptors, IFN- is uniquely positioned to prime the host immune response and provide an effective antineoplastic- and antiviral-immune response. IFN- stimulates the innate cell-mediated response and then participates in the transition of the initial host innate response into an effective adaptive-immune response. IFN- also drives the adaptive cell-mediated CD8+ T-cell response and helps to maintain a CD4+ Th1-cell population balance for an effective antineoplastic and antiviral host defense. This review will describe the current state of knowledge of IFN- as an immunoregulatory protein and address specific issues of IFN- as an immunotherapeutic for antineoplastic and antiviral diseases.
Key Words: antiviral therapy • antitumor therapy • immunological therapy
This article has been cited by other articles:
|
|
 |
|
  M.-L. Baron, D. Gauchat, R. La Motte-Mohs, N. Kettaf, A. Abdallah, T. Michiels, J.-C. Zuniga-Pflucker, and R.-P. Sekaly TLR Ligand-Induced Type I IFNs Affect Thymopoiesis J. Immunol., June 1, 2008; 180(11): 7134 - 7146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yarilina, E. DiCarlo, and L. B. Ivashkiv Suppression of the Effector Phase of Inflammatory Arthritis by Double-Stranded RNA Is Mediated by Type I IFNs J. Immunol., February 15, 2007; 178(4): 2204 - 2211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Hoene, M. Peiser, and R. Wanner Human monocyte-derived dendritic cells express TLR9 and react directly to the CpG-A oligonucleotide D19 J. Leukoc. Biol., December 1, 2006; 80(6): 1328 - 1336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Schmidlin, W. Dontje, F. Groot, S. J. Ligthart, A. D. Colantonio, M. E. Oud, E. J. Schilder-Tol, M. Spaargaren, H. Spits, C. H. Uittenbogaart, et al. Stimulated plasmacytoid dendritic cells impair human T-cell development Blood, December 1, 2006; 108(12): 3792 - 3800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dolganiuc, S. Chang, K. Kodys, P. Mandrekar, G. Bakis, M. Cormier, and G. Szabo Hepatitis C Virus (HCV) Core Protein-Induced, Monocyte-Mediated Mechanisms of Reduced IFN-{alpha} and Plasmacytoid Dendritic Cell Loss in Chronic HCV Infection J. Immunol., November 15, 2006; 177(10): 6758 - 6768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Groot, T. M. M. van Capel, M. L. Kapsenberg, B. Berkhout, and E. C. de Jong Opposing roles of blood myeloid and plasmacytoid dendritic cells in HIV-1 infection of T cells: transmission facilitation versus replication inhibition Blood, September 15, 2006; 108(6): 1957 - 1964. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Sharif, D. Sosic, C. V. Rothlin, E. Kelly, G. Lemke, E. N. Olson, and L. B. Ivashkiv Twist mediates suppression of inflammation by type I IFNs and Axl J. Exp. Med., August 7, 2006; 203(8): 1891 - 1901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Lopez, J. S. Yount, T. Hermesh, and T. M. Moran Sendai Virus Infection Induces Efficient Adaptive Immunity Independently of Type I Interferons J. Virol., May 1, 2006; 80(9): 4538 - 4545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Lopez, J. S. Yount, and T. M. Moran Toll-like receptor-independent triggering of dendritic cell maturation by viruses. J. Virol., April 1, 2006; 80(7): 3128 - 3134. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lee, C. C. N. Wu, K. J. Lee, T.-H. Chuang, K. Katakura, Y.-T. Liu, M. Chan, R. Tawatao, M. Chung, C. Shen, et al. Activation of anti-hepatitis C virus responses via Toll-like receptor 7 PNAS, February 7, 2006; 103(6): 1828 - 1833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Audige, E. Schlaepfer, H. Joller, and R. F. Speck Uncoupled Anti-HIV and Immune-Enhancing Effects when Combining IFN-{alpha} and IL-7 J. Immunol., September 15, 2005; 175(6): 3724 - 3736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Carotenuto, D. van Riel, A. Artsen, S. Bruijns, F. G. Uytdehaag, J. D. Laman, A. B. van Nunen, P. E. Zondervan, R. A. De Man, A. D. Osterhaus, et al. Antiviral Treatment with Alpha Interferon Up-Regulates CD14 on Liver Macrophages and Its Soluble Form in Patients with Chronic Hepatitis B Antimicrob. Agents Chemother., February 1, 2005; 49(2): 590 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. B. Gurney, A. D. Colantonio, B. Blom, H. Spits, and C. H. Uittenbogaart Endogenous IFN-{alpha} Production by Plasmacytoid Dendritic Cells Exerts an Antiviral Effect on Thymic HIV-1 Infection J. Immunol., December 15, 2004; 173(12): 7269 - 7276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yamamoto, H. Nagano, M. Sakon, H. Wada, H. Eguchi, M. Kondo, B. Damdinsuren, H. Ota, M. Nakamura, H. Wada, et al. Partial Contribution of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)/TRAIL Receptor Pathway to Antitumor Effects of Interferon-{alpha}/5-Fluorouracil against Hepatocellular Carcinoma Clin. Cancer Res., December 1, 2004; 10(23): 7884 - 7895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Treusch, R. Vonthein, M. Baur, I. Gunaydin, S. Koch, N. Stubiger, A. K. Eckstein, H.-H. Peter, T. Ness, M. Zierhut, et al. Influence of human recombinant interferon-{alpha}2a (rhIFN-{alpha}2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease Rheumatology, October 1, 2004; 43(10): 1275 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Donnelly, F. Sheikh, S. V. Kotenko, and H. Dickensheets The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain J. Leukoc. Biol., August 1, 2004; 76(2): 314 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Carbonneil, H. Saidi, V. Donkova-Petrini, and L. Weiss Dendritic cells generated in the presence of interferon-{alpha} stimulate allogeneic CD4+ T-cell proliferation: modulation by autocrine IL-10, enhanced T-cell apoptosis and T regulatory type 1 cells Int. Immunol., July 1, 2004; 16(7): 1037 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mattner, A. Wandersee-Steinhauser, A. Pahl, M. Rollinghoff, G. R. Majeau, P. S. Hochman, and C. Bogdan Protection against Progressive Leishmaniasis by IFN-{beta} J. Immunol., June 15, 2004; 172(12): 7574 - 7582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Tecchio, V. Huber, P. Scapini, F. Calzetti, D. Margotto, G. Todeschini, L. Pilla, G. Martinelli, G. Pizzolo, L. Rivoltini, et al. IFN{alpha}-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells Blood, May 15, 2004; 103(10): 3837 - 3844. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Kraus, J. F. Lau, J.-P. Parisien, and C. M. Horvath A Hybrid IRF9-STAT2 Protein Recapitulates Interferon-stimulated Gene Expression and Antiviral Response J. Biol. Chem., April 4, 2003; 278(15): 13033 - 13038. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Brod Ingested Type I Interferon: State of the Art as Treatment for Autoimmunity Experimental Biology and Medicine, December 1, 2002; 227(11): 981 - 988. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
